Natural killer reprogramming in cutaneous T-cell lymphomas: Facts and hypotheses

To better understand the pathogenesis of Sézary cells, distinguish them from reactive skin-infltrating T-cells and improve disease treatment, efforts have been made to identify molecular targets deregulated by the malignant process. From immunophenotypic analysis and subtractive differential expression experiments to pan-genomic studies, many approaches have been used to identify markers of the disease. During the last decade several natural killer （NK） cell markers have been found aberrantly expressed at the surface of Sézary cells. In particular, KIR3DL2/CD158k, expressed by less than 2% of healthy individuals CD4＋ T-cells, is an excellent marker to identify and follow the tumor burden in the blood of Sézary syndrome patients. It may also represent a valuable target for specifc im-munotherapy. Other products of the NK cluster on chromosome 19q13 have been detected on Sézary cells, raising the hypothesis of an NK reprogramming process associated with the malignant transformation that may induce survival functions.

蕈样肉芽肿和Sezary综合征分类和分期的修订方案——国际皮肤淋巴瘤学会和欧洲癌症研究治疗特别工作组的建议（待续）

ISCL／EORTC推荐蕈样肉芽肿协作组使用皮肤T细胞淋巴瘤（Cutaneous T-cell lymphoma，CTCL）分类及分期修订方案。这个修订方案吸收了自1979年最初的指南发表以来的有关蕈样肉芽肿（Mycosis Fungoides，MF）和Sezary综合征（Sezary syndrome，SS）肿瘤细胞生物学和诊断技术的进展，明确目前影响研究机构和调查者之间有效交流和（或）MF及SS标准化临床实验发展的某些指标，而且为追踪其他有潜在预后意义的指标提供了一个平台。此外，鉴于皮肤淋巴瘤中非MF／非SS亚型预后和临床特点的差异，本方案是特别针对MF和SS的。除了对本修订方案的评估和分期程序做出推荐外，该文还对修订方案的论据做了讨论。